A Clinical Trial of Antiplatelets in Psoriasis

Inclusion criteria

• One of the following:

• A history of psoriasis as confirmed by a board-certified dermatologist OR
• A history of psoriatic arthritis as confirmed by a board-certified rheumatologist
• Age ≥ 18 & < 90 years
• Able and willing to provide written informed consent for the study
• English-speaking unless a translated informed consent form is approved
• No previous antiplatelet or anticoagulant use for 14 days prior to enrollment

Exclusion criteria

• A prior history of a myocardial infarction, stroke/TIA, or occlusive peripheral arterial disease
• Chronic antiplatelet/anticoagulant use that is not able to be stopped at least 14 days prior to study enrollment
• Uncontrolled hypertension resting systolic blood pressure > 180 mm Hg or diabetes HbA1c > 10%
• Known active cancer receiving treatment
• Pregnancy
• Anemia (hemoglobin < 9 mg/dl) or thrombocytopenia (Platelet count <75), or thrombocytosis (Platelet count >600)
• A history of severe bleeding or bleeding disorders
• Active gastrointestinal ulcer
• Active pathological bleeding.
• Chronic kidney disease (CrCl < 30ml/min)
• Congestive heart failure
• Known hypersensitivity to or allergy to aspirin, clopidogrel, or any of the components of the study capsules
• History of aspirin-exacerbated respiratory disease or asthma induced by salicylates or NSAIDs
• Currently breastfeeding
• Persons of childbearing potential unwilling to use acceptable contraception during the study